RAAB MICHAEL
Known title: President & CEOCIK: 0001321402
RAAB MICHAEL's purchase track record
RAAB MICHAEL has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | ARDX | $2K | +81.4% | +208.0% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 8,411 | $32K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 19,178 | $74K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 15,009 | $58K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 15,976 | $62K | 8/21/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,834 | $21K | 7/15/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,668 | $211K | 7/15/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 6/15/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $236K | 6/15/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 14,933 | $94K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 17,926 | $112K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 14,028 | $88K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,861 | $49K | 5/21/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 5/15/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $262K | 5/15/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,834 | $21K | 4/15/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,668 | $262K | 4/15/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 3/16/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $243K | 3/16/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 2/24/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $261K | 2/24/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 40,401 | $237K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,576 | $32K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2 | $11 | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1 | $6 | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2 | $11 | 2/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 446,220 | $0 | 1/23/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 46,887 | $260K | 11/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 45,687 | $271K | 8/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 46,817 | $191K | 5/20/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 5/2/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $177K | 5/2/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 4/4/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $191K | 4/4/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,834 | $21K | 3/7/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,668 | $223K | 3/7/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 570,217 | $0 | 2/25/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 22,964 | $129K | 2/20/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 1/31/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $223K | 1/31/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,833 | $21K | 1/7/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 41,666 | $221K | 1/7/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 25,000 | $25K | 12/10/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 25,000 | $132K | 12/10/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 25,000 | $134K | 11/25/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 31,980 | $153K | 11/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,743 | $13K | 11/11/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 25,000 | $25K | 10/28/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 25,000 | $148K | 10/28/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,500 | $45K | 10/11/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,000 | $18K | 9/26/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 35,000 | $35K | 9/11/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 35,000 | $196K | 9/11/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,500 | $47K | 8/27/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 32,225 | $189K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,229 | $7K | 8/12/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 30,000 | $169K | 7/29/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 30,000 | $30K | 7/29/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,500 | $45K | 7/15/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,310 | $15K | 6/28/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 35,000 | $35K | 6/13/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 35,000 | $233K | 6/13/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,500 | $50K | 5/29/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 31,484 | $246K | 5/21/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,000 | $24K | 5/14/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 30,000 | $30K | 4/29/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 30,000 | $192K | 4/29/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,500 | $53K | 4/15/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,518 | $11K | 4/1/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 22,917 | $200K | 2/20/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 475,000 | $0 | 1/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 11,368 | $50K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 11,419 | $41K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 11,357 | $41K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 13,449 | $40K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 250,000 | $0 | 1/5/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 162 | $314 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 121 | $235 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,936 | $12K | 11/22/2022 | View on chart |
| ARDX | ▲ Buy | Open Market | 3,000 | $2K | 8/31/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 54 | $53 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 76 | $74 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,016 | $6K | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,144 | $1K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 101,480 | $66K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,124 | $4K | 5/20/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,229 | $4K | 2/22/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 150,000 | $0 | 1/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,607 | $3K | 11/22/2021 | View on chart |
| ARDX | ▲ Buy | Grant | 300,000 | $0 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.